Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-012: MK-1084 + cetuximab + mFOLFOX6 vs mFOLFOX6 ± bevacizumab in KRAS G12C metastatic colorectal cancer
jRCT2031250265Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of calderasib in colorectal adenocarcinoma (3 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities (DLTs) in Part 1, Adverse events (AEs) in Part 1 and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
calderasib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250265.